cIAP1 Ligand-Linker Conjugates 8 are specialized chemical tools designed for use in the development of PROTAC molecules (Proteolysis Targeting Chimeras). This product serves as an E3 ligase ligand-linker conjugate, specifically targeting the cellular inhibitor of apoptosis protein 1 (cIAP1) E3 ligase. It is supplied as a ready-to-use intermediate, facilitating the rapid synthesis of custom PROTACs or molecular glue degraders by attaching a ligand for target protein engagement. cIAP1 Ligand-Linker Conjugates play a crucial role in harnessing the ubiquitin-proteasome system, enabling selective degradation of disease-associated proteins for preclinical research in oncology, neurodegeneration, and other therapeutic areas. As a vital building block for targeted protein degradation technologies, this conjugate streamlines the generation of potent, selective, and innovative drug candidates aimed at advancing next-generation therapeutics.
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
cIAP1 Ligand-Linker Conjugates 8 are cutting-edge chemical tools designed specifically for use in targeted protein degradation research, particularly in the development of PROTAC (Proteolysis Targeting Chimera) molecules. These conjugates feature a finely tuned cIAP1 (cellular Inhibitor of Apoptosis Protein 1) ligand connected to a chemically optimized linker, facilitating efficient assembly of bifunctional PROTACs.
Mechanism
The mechanism of cIAP1 Ligand-Linker Conjugates 8 revolves around harnessing the ubiquitin-proteasome system via cIAP1 E3 ligase recruitment. When incorporated into PROTACs, the cIAP1-specific ligand binds to the cIAP1 E3 ligase, while the other end of the chimera targets the protein of interest (POI). This induced proximity leads to the ubiquitination of the POI, marking it for proteasomal degradation. The linker plays a crucial role in optimizing the spatial orientation and flexibility for effective ternary complex formation between cIAP1, the linker-conjugate, and the target protein.
Applications
cIAP1 Ligand-Linker Conjugates 8 are invaluable in the design and synthesis of PROTACs targeting a wide range of disease-relevant proteins. Key applications include cancer research, neurodegeneration studies, and chemical biology investigations where selective protein knockdown is required. These conjugates accelerate drug discovery programs by enabling rapid prototyping of novel PROTACs and facilitate mechanistic studies on protein degradation pathways mediated by cIAP1.
The cIAP1 Ligand-Linker Conjugates 8 play a pivotal role in the development of PROTACs by facilitating targeted protein degradation through E3 ligase recruitment. These conjugates offer an optimal balance of stability and reactivity, enhancing the efficacy of protein degradation applications. The following provides a detailed description of this molecule's linker, ligand, and recommended target protein ligands.
Linker: The linker in this molecule is a medium-length, flexible polyethylene glycol (PEG) chain that enhances solubility and bioavailability. Its non-cleavable nature ensures stability within the cellular environment, maintaining the integrity of the conjugate during target engagement.
Ligand: The ligand is a small-molecule mimic of the cIAP1 protein, featuring a bicyclic core structure. This configuration promotes high-affinity binding to the E3 ligase, ensuring effective recruitment and subsequent ubiquitination of the target protein.
Reactive Site: The reactive site is an amine-functionalized terminus designed for coupling with target protein ligands via amide bond formation. This site is suitable for reactions such as amidation or reductive amination, facilitating stable and covalent attachment.
Recommended Target Protein Ligand: A compatible warhead for this molecule is a small-molecule inhibitor with an electrophilic moiety, such as a carbonyl or sulfonyl fluoride group. These warheads offer the advantage of forming covalent bonds with nucleophilic residues on the target protein, enhancing specificity and efficacy in targeted protein degradation studies.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.